Literature DB >> 2506399

Establishment and characterization of two human myeloma cell lines secreting kappa light chains.

O Eton1, D A Scheinberg, A N Houghton.   

Abstract

A small number of human myelomas have been established as long term cultured cell lines. We report the characteristics of two new cell lines, designated SK-MM-1 and SK-MM-2, derived from 73 attempts to culture myeloma specimens. Both cell lines were grown from myeloma patients with hypogammaglobulinemia, kappa light chain proteinuria, and plasma cell leukemia. SK-MM-1 and SK-MM-2 had a plasmacytoid morphology, grew in RPMI complete medium with doubling times of 32 and 60 hr, respectively, and did not express Epstein-Barr virus nuclear antigen. Both cell lines secreted kappa light chains (0.9 and 1.1 micrograms/10(6) cells/ml per 48 hr for SK-MM-1 and SK-MM-2, respectively) but no heavy chains. SK-MM-1 and SK-MM-2 expressed the pan-B cell marker B1 and the late B cell/plasma cell marker BL3. In addition, SK-MM-2 expressed late B cell/plasma cell markers OKT10 and PCA-1. Neither cell line expressed T lymphocyte, myeloid, or early B lymphocyte markers. The presence of distinctive kappa and heavy chain gene rearrangements supported the clonal origin of both cell lines from kappa light chain-producing B cells. The two cell lines were markedly aneuploid and both carried a 14q+ marker chromosome. Human myeloma cell lines lacking heavy chain secretion may be useful to elucidate mechanisms of immunoglobulin gene regulation and to construct human-human hybridomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506399

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

Authors:  P L Bergsagel; M Chesi; E Nardini; L A Brents; S L Kirby; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

2.  Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms.

Authors:  I Ramasamy; M Brisco; A Morley
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

3.  Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

Authors:  Fabricio de Carvalho; Erico T Costa; Anamaria A Camargo; Juliana C Gregorio; Cibele Masotti; Valeria C C Andrade; Bryan E Strauss; Otavia L Caballero; Djordje Atanackovic; Gisele W B Colleoni
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

4.  UBE2G1 governs the destruction of cereblon neomorphic substrates.

Authors:  Stephanie Weng; Mary Matyskiela; Gang Lu; Xinde Zheng; Wei Fang; Scott Wood; Christine Surka; Reina Mizukoshi; Chin-Chun Lu; Derek Mendy; In Sock Jang; Kai Wang; Mathieu Marella; Suzana Couto; Brian Cathers; James Carmichael; Philip Chamberlain; Mark Rolfe
Journal:  Elife       Date:  2018-09-20       Impact factor: 8.140

5.  Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically.

Authors:  Mariaserena Giliberto; Deepak B Thimiri Govinda Raj; Andrea Cremaschi; Sigrid S Skånland; Alexandra Gade; Geir E Tjønnfjord; Fredrik Schjesvold; Ludvig A Munthe; Kjetil Taskén
Journal:  Mol Oncol       Date:  2022-03-12       Impact factor: 6.603

6.  A comparison between protein profiles of B cell subpopulations and mantle cell lymphoma cells.

Authors:  Henrik Stranneheim; Lukas M Orre; Janne Lehtiö; Jenny Flygare
Journal:  Proteome Sci       Date:  2009-11-23       Impact factor: 2.480

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.